- Home
- GLBZ vs SYBX Comparison
GLBZ vs SYBX Comparison
Compare GLBZ & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLBZ
- SYBX
- Stock Information
- Founded
- GLBZ 1949
- SYBX N/A
- Country
- GLBZ United States
- SYBX United States
- Employees
- GLBZ N/A
- SYBX N/A
- Industry
- GLBZ Major Banks
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- GLBZ Finance
- SYBX Health Care
- Exchange
- GLBZ Nasdaq
- SYBX Nasdaq
- Market Cap
- GLBZ 14.1M
- SYBX 13.9M
- IPO Year
- GLBZ N/A
- SYBX N/A
- Fundamental
- Price
- GLBZ $5.25
- SYBX $1.76
- Analyst Decision
- GLBZ
- SYBX
- Analyst Count
- GLBZ 0
- SYBX 0
- Target Price
- GLBZ N/A
- SYBX N/A
- AVG Volume (30 Days)
- GLBZ 16.1K
- SYBX 67.1K
- Earning Date
- GLBZ 07-29-2025
- SYBX 08-07-2025
- Dividend Yield
- GLBZ 1.86%
- SYBX N/A
- EPS Growth
- GLBZ N/A
- SYBX N/A
- EPS
- GLBZ 0.01
- SYBX 0.21
- Revenue
- GLBZ $11,536,000.00
- SYBX N/A
- Revenue This Year
- GLBZ N/A
- SYBX N/A
- Revenue Next Year
- GLBZ N/A
- SYBX N/A
- P/E Ratio
- GLBZ $409.94
- SYBX $8.30
- Revenue Growth
- GLBZ N/A
- SYBX N/A
- 52 Week Low
- GLBZ $4.02
- SYBX $0.90
- 52 Week High
- GLBZ $6.99
- SYBX $1.96
- Technical
- Relative Strength Index (RSI)
- GLBZ 50.25
- SYBX 77.41
- Support Level
- GLBZ $4.87
- SYBX $1.19
- Resistance Level
- GLBZ $5.84
- SYBX $1.96
- Average True Range (ATR)
- GLBZ 0.35
- SYBX 0.13
- MACD
- GLBZ -0.03
- SYBX 0.06
- Stochastic Oscillator
- GLBZ 37.62
- SYBX 66.67
About GLBZ Glen Burnie Bancorp
Glen Burnie Bancorp is a bank holding company for The Bank of Glen Burnie. It offers retail and commercial banking services such as checking, savings, loans, mobile banking, online banking, wire transfer, ACH services, debit cards, automated teller machines, and safe deposit boxes among others. The bank generates its revenue in the form of interest income. All of the revenues are earned within the United States.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.